Inderes is a hub connecting investors and listed companies. We are home to over 70 000 investors and 400 Nordic listed companies. Log in to keep up with your favourite companies!
The companies pilot Nightingale Health's Remote Health Check service with a group of 23andMe consumer members. If the pilot succeeds, we estimate that Nightingale’s service can be integrated into 23andMe’s subscription services.
SciBase announced a collaboration agreement focused on skin cancer with Unified Health, a large healthcare group based in Los Angeles. Unified Health has nine clinics in Southern California.
The partnership covers a service contract between Nightingale and Boston Heart Diagnostics Corporation to sell Nightingale's Health Check service in the US.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
H&M’s Q2 was strong as sales grew and EBIT improved y/y and topped our forecasts, although they were in line with the consensus. H&M, however, sees more headwinds in H2 than previously and hence its EBIT margin target of 10% looks more challenging for this year, according to the company.
Nexstim announced on Thursday that it had agreed on a digitalization and innovation loan with Finnvera. The loan of 1.5 MEUR is intended for the product development of the NBS6 system. We will include the loan in our model in connection with the next company update or in the H1 preview at the latest.
Kreate has signed an extension with the Finnish Transport Agency for two previous railway projects that Kreate is currently building between Kytömaa and Ainola. The signed contract is worth 34 MEUR.
Trading in the company ended yesterday, Thursday, on the Finnish First North market and will start today on the Swedish First North Premier Sweden market according to the previously announced schedule. As a result, the share will be quoted in SEK from now on.
OptiCept has announced a partnership with the foodtech company Simply No Waste, marking its entry into the extraction of residual products and side streams industry. We see it as positive that OptiCept will gain access to Simply No Waste's production facility to test and develop new applications at a seemingly low cost. However, this news does not directly impact our forecasts or our view on the stock.
The extensive research of 40+ pages on cybersecurity company WithSecure is published! Analyst Atte Riikola summarizes the case from several angles and shares his view on current recommendation.
We have initiated coverage of Herantis Pharma, a drug development company focused on neurodegenerative diseases. In this interview analyst Antti Siltanen sheds light on what the company does, what its drug candidate HER-096 is all about, competing drug candidates and other pressing questions regarding the company.
Nexstim announced on Tuesday that the company had raised EUR 650,000 with a convertible bond. We feel the bond was arranged on reasonable terms for the shareholders, with an interest rate of 7% and a conversion price of EUR 2.87. The bond strengthens Nexstim’s working capital and balance sheet as the company strives for positive cash flow.
UB's operational performance in recent years has been very strong and the company's results have grown rapidly. While challenging market conditions will slow new sales in the short term, the company is well positioned to continue its healthy growth in line with the rest of the asset management market, particularly over the longer term.
H&M will report its Q2’24 (March-May) results on Thursday at 8:00 am CET. We expect revenue to be flattish in local currencies, but EBIT to improve clearly, supported by both gross margin improvement and lower opex. The company has said its targeting 10% EBIT margin in 2024, which looks optimistic to us as we expect only 7.9%, while the consensus is at 8.9%.
OptiCept, through its partner BCC, has announced the signing of evaluation agreements with several prominent forestry companies and growers in South Africa. According to the announcement, the agreements currently involve three companies, with five more expected to join. These companies will evaluate OptiCept's patented OptiBoost technology to improve the rooting and quality of forestry cuttings in their operations. According to OptiCept, these agreements could potentially lead to the treatment of more than 100 million cuttings per year. While we view the news as positive and indicative of significant interest in the technology from major players, we are not making any changes to our estimates and recommendations at this time given the early stage of the projects.
We find the acquisition of Jun Group to be a good strategic fit for Verve and we view the acquisition price as highly compelling. Despite the diminishing effects following the acquisition, Verve’s risk profile remains on the high side, but we believe that the company’s valuation is low at current share price levels and presents an attractive risk/reward ratio.
Since the rocket-like growth at the start of the decade, the company has faced a pressure test in the past quarters due to the destocking of the largest customer, but we feel Incap is passing the test with flying colors.
Mendus announced on Thursday that the company will present new clinical data on vididencel for ovarian cancer at the ESMO Gynaecological Cancers Annual Congress.
Herantis is a drug development company focused on neurodegenerative diseases. Herantis currently has one candidate in the clinical Phase I, HER-096, which the company develops as a disease-modifying drug for Parkinson's disease.